By the time this paper was published the existence of C reactive protein had been known for at least 27 years-that is, almost 60 years ago. While originally thought to be a specific antibody against the pneumococcus it was eventually found in humans as a serum reaction to numerous inflammatory conditions and to tissue necrosis. This paper described the further purification by crystallisation of the protein and the production on a commercial scale of a specific antiserum for C reactive protein.
The Several rapid quantitative assays are now used and it has a singular advantage of responding vigorously within 6-10 hours of the onset of bacterial (though not viral) infection. 2 Of the other acute phase reactants that have been studied in rheumatic diseases the mucoprotein tyrosine has been shown to be more 'stable' in the face of treatments with antibiotics and steroids. If micro methods were available for some of these other reactants they might assist even more than C reactive protein or plasma viscosity in establishing the presence of active infection in the newborn-or is it easier just to treat all preterm babies prophylactically with wide spectrum antibiotics? Even if the latter course is adopted such tests might help to identify those babies who were 'escaping' from such protection and to recognise the need for a change in antibiotic. Nitroblue tetrazolium and an acridine orange leucocyte cytosine test are also being studied in the apparently never ending search for a reliable, preferably single, test for neonatal infection.3
